Hot Features
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-sm... Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0279 | 26.2959472196 | 0.1061 | 0.1688 | 0.095 | 18192811 | 0.1113465 | CS |
| 4 | -0.011 | -7.58620689655 | 0.145 | 0.1688 | 0.095 | 6110415 | 0.1152943 | CS |
| 12 | -0.048 | -26.3736263736 | 0.182 | 0.3583 | 0.095 | 11861425 | 0.20232813 | CS |
| 26 | -0.5115 | -79.2408985283 | 0.6455 | 2.83 | 0.095 | 9875812 | 0.64006688 | CS |
| 52 | -10.266 | -98.7115384615 | 10.4 | 10.755 | 0.095 | 5333512 | 0.87824626 | CS |
| 156 | -7.366 | -98.2133333333 | 7.5 | 33.66 | 0.095 | 4619179 | 1.07629873 | CS |
| 260 | -7.366 | -98.2133333333 | 7.5 | 33.66 | 0.095 | 4619179 | 1.07629873 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.